Bicycle Therapeutics (BCYC) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $3.46, -3.89% vs the prior close of $3.60.
- Volume 565.55K shares, 1.4x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
BCYC slides 3.9% to $3.46. Closed at $3.46, -3.89% vs the prior close of $3.60. Day range $3.42–$3.60, opened at $3.58.
BCYC daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — BCYC slides 3.9% to $3.46
- Closed at $3.46, -3.89% vs the prior close of $3.60. Day range $3.42–$3.60, opened at $3.58.
- Volume was 565.55K shares, 1.4x its 50-day average of 410.85K.
- Price is -11.6% vs its 50-day average ($3.91) and -26.6% vs its 200-day average ($4.71).
- 52-week range $3.33–$9.08; today's close sits at 2% of that range, 61.9% below the 52-week high.
Oct 15, 2026 — BCYC rises 2.6% to $3.60
- Closed at $3.60, +2.56% vs the prior close of $3.51. Day range $3.50–$3.64, opened at $3.51.
- Volume was 411.50K shares, 1.0x its 50-day average of 408.38K.
- Price is -8.3% vs its 50-day average ($3.93) and -23.9% vs its 200-day average ($4.73).
- 52-week range $3.33–$9.08; today's close sits at 5% of that range, 60.4% below the 52-week high.
Oct 14, 2026 — BCYC slides 3.3% to $3.51, 3 down days in a row
- Closed at $3.51, -3.31% vs the prior close of $3.63. Day range $3.50–$3.76, opened at $3.63.
- Volume was 438.30K shares, 1.1x its 50-day average of 403.21K.
- Price is -10.7% vs its 50-day average ($3.93) and -26.1% vs its 200-day average ($4.75).
- 52-week range $3.33–$9.08; today's close sits at 3% of that range, 61.3% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — BCYC slides 4.5% to $3.63
- Closed at $3.63, -4.47% vs the prior close of $3.80. Day range $3.63–$3.88, opened at $3.81.
- Volume was 457.20K shares, 1.1x its 50-day average of 400.87K.
- Price is -7.9% vs its 50-day average ($3.94) and -23.8% vs its 200-day average ($4.76).
- 52-week range $3.33–$9.08; today's close sits at 5% of that range, 60.0% below the 52-week high.
Oct 12, 2026 — BCYC dips 2.3% to $3.80
- Closed at $3.80, -2.31% vs the prior close of $3.89. Day range $3.79–$3.91, opened at $3.89.
- Volume was 233.30K shares, 0.6x its 50-day average of 402.93K — lighter than usual.
- Price is -3.7% vs its 50-day average ($3.95) and -20.5% vs its 200-day average ($4.78).
- 52-week range $3.33–$9.10; today's close sits at 8% of that range, 58.2% below the 52-week high.
Oct 9, 2026 — BCYC rises 2.1% to $3.89
- Closed at $3.89, +2.10% vs the prior close of $3.81. Day range $3.78–$3.92, opened at $3.81.
- Volume was 300.60K shares, 0.7x its 50-day average of 405.29K.
- Price is -1.4% vs its 50-day average ($3.95) and -18.9% vs its 200-day average ($4.80).
- 52-week range $3.33–$9.16; today's close sits at 10% of that range, 57.5% below the 52-week high.
Oct 8, 2026 — BCYC rises 2.1% to $3.81
- Closed at $3.81, +2.14% vs the prior close of $3.73. Day range $3.62–$3.81, opened at $3.71.
- Volume was 337.70K shares, 0.8x its 50-day average of 405.58K.
- Price is -3.5% vs its 50-day average ($3.95) and -20.8% vs its 200-day average ($4.81).
- 52-week range $3.33–$9.16; today's close sits at 8% of that range, 58.4% below the 52-week high.
Oct 7, 2026 — BCYC dips 1.6% to $3.73
- Closed at $3.73, -1.58% vs the prior close of $3.79. Day range $3.68–$3.81, opened at $3.75.
- Volume was 472.60K shares, 1.2x its 50-day average of 402.55K.
- Price is -5.6% vs its 50-day average ($3.95) and -22.7% vs its 200-day average ($4.83).
- 52-week range $3.33–$9.16; today's close sits at 7% of that range, 59.3% below the 52-week high.
Oct 6, 2026 — BCYC slides 5.5% to $3.79
- Closed at $3.79, -5.49% vs the prior close of $4.01. Day range $3.73–$4.03, opened at $4.02.
- Volume was 620.70K shares, 1.6x its 50-day average of 396.21K.
- Price is -4.2% vs its 50-day average ($3.95) and -21.7% vs its 200-day average ($4.84).
- 52-week range $3.33–$9.16; today's close sits at 8% of that range, 58.6% below the 52-week high.
Oct 5, 2026 — BCYC jumps 18.6% to $4.01 on 5.0x normal volume
- Closed at $4.01, +18.64% vs the prior close of $3.38. Day range $3.61–$4.04, opened at $3.62.
- Volume was 1.84M shares, 5.0x its 50-day average of 370.79K — unusually heavy trading.
- Price is +1.3% vs its 50-day average ($3.96) and -17.5% vs its 200-day average ($4.86).
- 52-week range $3.33–$9.16; today's close sits at 12% of that range, 56.2% below the 52-week high.
Oct 2, 2026 — BCYC slides 5.1% to $3.38, a 52-week low on 2.0x normal volume
- Closed at $3.38, -5.06% vs the prior close of $3.56. Day range $3.33–$3.69, opened at $3.65.
- Volume was 728.70K shares, 2.0x its 50-day average of 359.30K — unusually heavy trading.
- Price is -14.5% vs its 50-day average ($3.96) and -30.7% vs its 200-day average ($4.88).
- 52-week range $3.33–$9.16; today's close sits at 1% of that range, 63.1% below the 52-week high.
BCYC latest news & SEC filings
Every SEC filing by or about BCYC in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
- Perry Jennifer Scott sold 30 shares at $3.57 (≈$107) on Oct 5, 2026; now holds 89,928
- Perry Jennifer Scott sold 326 shares at $3.78 (≈$1.23K) on Oct 5, 2026; now holds 89,602
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Swanton Robert Charles sold 3,431 shares at $3.47 (≈$11.91K) on Oct 2, 2026; now holds 15,782
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Skynner Michael sold 1,942 shares at $3.47 (≈$6.74K) on Oct 2, 2026; now holds 155,229
- Skynner Michael sold 503 shares at $3.57 (≈$1.80K) on Oct 5, 2026; now holds 154,726
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hannay Michael Charles Ferguson sold 1,572 shares at $3.47 (≈$5.45K) on Oct 2, 2026; now holds 92,803
- Hannay Michael Charles Ferguson sold 242 shares at $3.57 (≈$864) on Oct 5, 2026; now holds 92,561
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Perry Jennifer Scott sold 1,094 shares at $3.47 (≈$3.80K) on Oct 2, 2026; now holds 89,958
- Perry Jennifer Scott sold 80 shares at $3.56 (≈$285) on Oct 5, 2026; now holds 89,878
- Perry Jennifer Scott sold 326 shares at $3.78 (≈$1.23K) on Oct 5, 2026; now holds 89,552
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lee Kevin sold 6,167 shares at $3.47 (≈$21.40K) on Oct 2, 2026; now holds 597,504
- Lee Kevin sold 1,638 shares at $3.57 (≈$5.85K) on Oct 5, 2026; now holds 595,866
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 20, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 30, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $629.00K (prior year $2.92M) (-78.5% vs Jun 30, 2025)
- Net income: -$50.33M (prior year -$78.95M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.72 (prior year -$1.14) (loss narrowed vs Jun 30, 2025)
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade BCYC
- Last results release: Jul 30, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Mar 17, 2026, Oct 30, 2025. Based on that rhythm, the next report is likely around Oct 29, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.48% (largest 18.6%). That is a volatile stock.
- Liquidity: about 499.41K shares (≈$1.73M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $3.46 vs a range of $3.33–$9.08 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Michael Charles Ferguson Hannay sold 255 shares on Jul 6, 2026.
- Latest filings: 8-K Aug 20, 2026; 10-Q Jul 30, 2026; 8-K Jul 30, 2026.
- Share count: 30.04M shares outstanding (May 1, 2023), +1.3% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
BCYC market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 3.58 | 3.60 | 3.42 | 3.46 | 565.55K |
| Oct 15, 2026 | 3.51 | 3.64 | 3.50 | 3.60 | 411.50K |
| Oct 14, 2026 | 3.63 | 3.76 | 3.50 | 3.51 | 438.30K |
| Oct 13, 2026 | 3.81 | 3.88 | 3.63 | 3.63 | 457.20K |
| Oct 12, 2026 | 3.89 | 3.91 | 3.79 | 3.80 | 233.30K |
| Oct 9, 2026 | 3.81 | 3.92 | 3.78 | 3.89 | 300.60K |
| Oct 8, 2026 | 3.71 | 3.81 | 3.62 | 3.81 | 337.70K |
| Oct 7, 2026 | 3.75 | 3.81 | 3.68 | 3.73 | 472.60K |
| Oct 6, 2026 | 4.02 | 4.03 | 3.73 | 3.79 | 620.70K |
| Oct 5, 2026 | 3.62 | 4.04 | 3.61 | 4.01 | 1.84M |
| Oct 2, 2026 | 3.65 | 3.69 | 3.33 | 3.38 | 728.70K |
| Oct 1, 2026 | 3.67 | 3.74 | 3.55 | 3.56 | 379.90K |
| Sep 30, 2026 | 3.69 | 3.77 | 3.66 | 3.68 | 295.10K |
| Sep 29, 2026 | 3.72 | 3.77 | 3.63 | 3.65 | 206.20K |
| Sep 28, 2026 | 3.69 | 3.81 | 3.58 | 3.71 | 442.50K |
| Sep 25, 2026 | 3.73 | 3.73 | 3.65 | 3.68 | 238.90K |
| Sep 24, 2026 | 3.66 | 3.95 | 3.66 | 3.73 | 820.00K |
| Sep 23, 2026 | 3.72 | 3.72 | 3.57 | 3.60 | 374.20K |
| Sep 22, 2026 | 3.67 | 3.83 | 3.65 | 3.73 | 554.70K |
| Sep 21, 2026 | 3.70 | 3.77 | 3.63 | 3.63 | 266.50K |
About Bicycle Therapeutics
Bicycle Therapeutics (BCYC) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CAMBRIDGE, United Kingdom. State of incorporation: United Kingdom. Fiscal year ends December 31. SEC CIK 1761612.
BCYC board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| L.P. 667, | Director | Jan 6, 2026 |
| Bros. Advisors Lp Baker | Director | Jan 6, 2026 |
| Felix Baker | Director | Jan 6, 2026 |
| Julian Baker | Director | Jan 6, 2026 |
| Bros. Advisors (Gp) Llc Baker | Director | Jan 6, 2026 |
| Brothers Life Sciences Lp Baker | Director | Jan 6, 2026 |
| Janice Bourque | Director | Jan 6, 2026 |
| Roger D Dansey | Director | Jan 6, 2026 |
| Jose-Carlos Gutierrez-Ramos | Director | Jan 6, 2026 |
| Herve Hoppenot | Director | Jan 6, 2026 |
| Kevin Lee | CHIEF EXECUTIVE OFFICER | Jul 7, 2026 |
| Alessandro Riva | Director | Jan 6, 2026 |
| Stephen H. Sands | Director | Jan 6, 2026 |
| Robert Charles Swanton | Director | Jan 6, 2026 |
| Gregory Paul Winter | Director | Jan 6, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Michael Charles Ferguson Hannay | CHIEF PROD & SUPPLY CHAIN OFF | Jul 17, 2026 |
| Kevin Lee | CHIEF EXECUTIVE OFFICER | Jul 7, 2026 |
| Alistair Milnes | CHIEF OPERATING OFFICER | Jan 6, 2026 |
| Jennifer Scott Perry | Chief Operating Officer | Jul 17, 2026 |
| Michael Skynner | CHIEF SCIENTIFIC OFFICER | Jul 17, 2026 |
| Travis Alvin Thompson | Chief Financial Officer | Jul 17, 2026 |
| Alethia Young | Chief Financial Officer | Jan 6, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 6, 2026 | Michael Charles Ferguson Hannay | Sale | 255 | $4.31 |
| Jul 6, 2026 | Michael Charles Ferguson Hannay | Sale | 255 | $4.31 |
| Jul 6, 2026 | Michael Charles Ferguson Hannay | Sale | 255 | $4.31 |
| Jul 6, 2026 | Michael Charles Ferguson Hannay | Sale | 255 | $4.31 |
| Jul 6, 2026 | Michael Skynner | Sale | 532 | $4.31 |
| Jul 6, 2026 | Michael Skynner | Sale | 532 | $4.31 |
| Jul 6, 2026 | Michael Skynner | Sale | 532 | $4.31 |
| Jul 6, 2026 | Michael Skynner | Sale | 532 | $4.31 |
| Jul 6, 2026 | Kevin Lee | Sale | 1,737 | $4.31 |
| Jul 6, 2026 | Kevin Lee | Sale | 1,737 | $4.31 |
| Jul 6, 2026 | Kevin Lee | Sale | 1,737 | $4.31 |
| Jul 6, 2026 | Kevin Lee | Sale | 1,737 | $4.31 |
| Jul 6, 2026 | Jennifer Scott Perry | Sale | 333 | $4.34 |
| Jul 6, 2026 | Jennifer Scott Perry | Sale | 43 | $4.31 |
| Jul 6, 2026 | Jennifer Scott Perry | Sale | 333 | $4.34 |
BCYC financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $72.59M | $-218.96M | -3.16 | $-249.68M |
| Dec 31, 2024 | $35.27M | $-169.03M | -2.90 | $-164.72M |
| Dec 31, 2023 | $26.98M | $-180.66M | -5.08 | $-60.63M |
| Dec 31, 2022 | $14.46M | $-112.72M | -3.80 | $-86.11M |
| Dec 31, 2021 | $11.70M | $-66.82M | -2.67 | $-14.79M |
Latest balance sheet: total assets $606.58M, total liabilities $96.32M, cash $510.05M (as of Jun 30, 2026).
BCYC earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 30, 2026 | 8-K Item 2.02 (results) | $4.01 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $4.72 |
| Mar 17, 2026 | 8-K Item 2.02 (results) | $5.07 |
| Oct 30, 2025 | 8-K Item 2.02 (results) | $8.76 |
| Aug 8, 2025 | 8-K Item 2.02 (results) | $7.65 |
| May 1, 2025 | 8-K Item 2.02 (results) | $9.08 |
| Feb 25, 2025 | 8-K Item 2.02 (results) | $11.10 |
| Oct 31, 2024 | 8-K Item 2.02 (results) | $23.44 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Feb 20, 2024 | 8-K Item 2.02 (results) | — |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on BCYC
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.